

It is the Society of Obstetricians and Gynaecologists of Canada (SOGC) policy to review the content 5 years after publication, at which time the document may be revised to reflect new evidence or the document may be archived.

No. 420, July 2021 (Replaces No. 240, April 2010)

Guideline No. 420: Cytomegalovirus Infection in Pregnancy

(En français : Infection à cytomégalo­virus pendant la grossesse)

The English document is the original version. In the event of any discrepancy between the English and French content, the English version prevails.

This clinical practice guideline was prepared by the authors and overseen by the SOGC Infectious Disease Committee. It was approved by the SOGC Guideline Management and Oversight Committee and SOGC Board of Directors.

This clinical practice guideline supersedes No. 240, published in April 2010.

Authors

Isabelle Boucoiran, MD, Montréal, QC
Mark Yudin, MD, Toronto, ON
Vanessa Poliquin, MD, Winnipeg, MB
Sheila Caddy, MD, Calgary, AB
Soren Gantt, MD, Vancouver, BC
Eliana Castillo, MD, Calgary, AB

SOGC Infectious Disease Committee (2020): Isabelle Boucoiran, Sheila Caddy, Eliana Castillo, Chelsea Elwood (co-chair), Deborah Money, Jennifer Nicholson, Martha Paynter, Vanessa Poliquin (co-chair), Julie van Schalkwyk, Heather Watson, Megan Williams, Jeffrey Man Hay Wong, Mark Yudin

Acknowledgements: The authors would like to acknowledge and thank Ms. Lisa Robinson and Mr. Robert Tetrault, founder of the Canadian CMV Foundation, for their invaluable input as patient-partners, and for the financial support to develop the patient infographic. Furthermore, the authors wish to acknowledge and thank Drs. Yoav Yinon and Dan Farine for their contributions to the original version of this guideline, Dr. Mina Majd (SOGC) for conducting the literature search, Dr. Laura Idarraga (University of Calgary) for preparing figures, Jamie Chalmers (Physician Assistant Student, University of Manitoba) for assistance in designing the infographic, and Chelsea Doktorchik (University of Calgary) for incorporating patients' feedback.

Disclosures: Statements were received from all authors. Dr. Isabelle Boucoiran reports funded grants and clinical trials by Ferring Pharmaceuticals. Dr. Soren Gantt reports research funding and/or consulting fees from Merck, Moderna, VBI vaccines, Meridian Bioscience and Altona Diagnostics related to cytomegalovirus. No other relationships or activities that could involve a conflict of interest were declared.

All authors have indicated that they meet the journal's requirements for authorship.

J Obstet Gynaecol Can 2021;43(7):893–908

<https://doi.org/10.1016/j.jogc.2021.05.015>

© 2021 The Society of Obstetricians and Gynaecologists of Canada/La Société des obstétriciens et gynécologues du Canada. Published by Elsevier Inc.

This document reflects emerging clinical and scientific advances as of the publication date and is subject to change. The information is not meant to dictate an exclusive course of treatment or procedure. Institutions are free to amend the recommendations. The SOGC suggests, however, that they adequately document any such amendments.

Informed consent: Everyone has the right and responsibility to make informed decisions about their care together with their health care providers. In order to facilitate this, the SOGC recommends that health care providers provide patients with information and support that is evidence-based, culturally appropriate, and personalized.

Language and inclusivity: The SOGC recognizes the importance to be fully inclusive and when context is appropriate, gender-neutral language will be used. In other circumstances, we continue to use gendered language because of our mission to advance women's health. The SOGC recognizes and respects the rights of all people for whom the information in this document may apply, including but not limited to transgender, non-binary, and intersex people. The SOGC encourages health care providers to engage in respectful conversation with their patients about their gender identity and preferred gender pronouns and to apply these guidelines in a way that is sensitive to each person's needs.

Weeks Gestation Notation: The authors follow the World Health Organization’s notation on gestational age: the first day of the last menstrual period is day 0 (of week 0); therefore, days 0 to 6 correspond to completed week 0, days 7 to 13 correspond to completed week 1, etc.

Keywords: cytomegalovirus infections; newborn screening; pregnancy

Corresponding author: Isabelle Boucoiran, isabelle.boucoiran@umontreal.ca

RECOMMENDED CHANGES IN PRACTICE

1. Providers should educate patients of child-bearing age, pregnant patients, or patients planning a pregnancy about cytomegalovirus and its sequelae. This will encourage patients to take preventive measures to reduce cytomegalovirus acquisition.
2. Providers should discuss all treatment options with patients infected with cytomegalovirus, and decisions should be made in a shared process involving providers and patients.

KEY MESSAGES

1. Cytomegalovirus is the most common congenital infection. Despite the high prevalence and serious consequences of congenital cytomegalovirus infection, only 15% of pregnant patients in Canada are aware of cytomegalovirus and its sequelae.
2. There is a lack of strong and consistent evidence for maternal cytomegalovirus infection screening during pregnancy and/or treatment of maternal infection (to prevent transmission to the fetus) or of established fetal infection. Therefore, awareness and prevention of cytomegalovirus acquisition are key. The recommended best practice is educating all pregnant patients or patients planning a pregnancy, and their families, about cytomegalovirus and the available preventive interventions.
3. Despite the challenges in diagnosing and treating congenital cytomegalovirus infection during pregnancy, cytomegalovirus-related disability can be mitigated, to some extent, through neonatal diagnosis and intervention, combined with Canada’s well-established programs for early hearing detection and intervention.

DEFINITIONS

Primary CMV infection in pregnancy: new CMV infection in a person who was CMV IgG negative before the pregnancy

Non-primary CMV infection in pregnancy: active CMV infection in a person with a previous infection (who was previously CMV IgG positive)

ABSTRACT

Objective: To provide an update on current recommendations for cytomegalovirus (CMV) infection during pregnancy. The objectives of this guideline are:

- To improve perinatal care providers’ awareness of the consequences of maternal CMV infection for the fetus and the infant;
- To emphasize the importance of educating patients about how to prevent CMV acquisition during pregnancy
- To raise perinatal care providers’ awareness of new developments in CMV screening and treatment
- To highlight that a substantial proportion of disability due to congenital CMV (cCMV) can be modified to some extent

Target Population: Patients of child-bearing age, pregnant patients, and patients planning a pregnancy.

Benefits, Harms, and Costs: The patient partners urged us to make awareness of preventive strategies a high priority, despite concern that discussing CMV with patients could cause unnecessary anxiety. CMV educational interventions have shown benefits from increased awareness of cCMV prevalence and preventive strategies among providers, patients, and families.

Evidence: We searched MEDLINE, EMBASE, and CENTRAL databases for CMV in pregnancy. The search terms were developed using MeSH terms and keywords (**Appendix**).

The results were filtered for articles published between January 2010 and October 2020 and systematic reviews, meta-analyses, clinical trials, and observational studies.

The main inclusion criteria were pregnant patients and infants, as the target population, and CMV infection, as the diagnosis of interest. Recommendations are graded according to the U.S. Preventive Services Task Force grade of recommendations and level of certainty.

Validation Methods: We collaborated with patient partners, including members of CMV Canada (cmvcanada.com). In formulating our recommendations, we included patients’ voices to add a unique and valuable perspective, thus ensuring that our recommendations are relevant to the patient–provider partnership.

Intended Audience: All perinatal health care providers.

RECOMMENDATIONS (grade and level of certainty in parentheses):

1. Pregnant patients with a mononucleosis-like illness or undifferentiated hepatitis should be investigated for cytomegalovirus infection (*C, low*).
2. To diagnose maternal cytomegalovirus infections and to differentiate primary from non-primary infections, this guideline recommends a combination of seroconversion (defined as documentation of a change from cytomegalovirus immunoglobulin G negative to positive), cytomegalovirus immunoglobulin M, and cytomegalovirus immunoglobulin G avidity testing (*B, moderate*).
3. A positive immunoglobulin M result alone should be interpreted with caution when determining when a CMV infection was acquired (*C, moderate*).
4. Breastfeeding is considered safe in patients who had CMV infection during pregnancy (*B, high*).
5. If primary maternal CMV infection is diagnosed during pregnancy, or abnormal sonographic findings suggest congenital CMV infection, pregnant patients should be offered an amniocentesis for confirmation of fetal congenital infection (cCMV) at least 8 weeks after the estimated time of maternal infection (*B, high*).
6. This guideline recommends discussing education and hygiene measures to prevent CMV acquisition with all patients, regardless of serologic status, before conception and through pregnancy, especially early in the antepartum period (*B, high*).
7. CMV hyperimmune globulin should not be used to prevent congenital CMV if a primary CVM infection is diagnosed during pregnancy (*B, low*).

8. In the case of documented primary CMV infection in the first trimester, early treatment with valacyclovir can be considered (*B, moderate*).
9. For established congenital CMV infections during pregnancy, decisions concerning treatment options should be made in a shared process involving patients and experienced teams (*C, low*).
10. In provinces where CMV IgG avidity testing is available, screening for CMV primary infection in the first trimester (using IgG and IgM antibodies followed by IgG avidity testing if the patient is IgM-positive) can be offered, especially in women at high risk (those who have a child under 3 years at home). CMV screening in pregnancy is not recommended in provinces where CMV IgG avidity testing is unavailable (*C, low*).

INTRODUCTION

Cytomegalovirus (CMV) is the most common infection acquired before birth (congenital infection). Congenital CMV infection (cCMV; defined as CMV infection that is acquired in utero [transplacentally] and is present at birth) is estimated to affect 1 of every 180 to 240 babies born in Canada^{1,2} (Figure 1). Although most infants with cCMV are healthy at birth, approximately 15% to 20% have permanent neurologic sequelae, most commonly sensorineural hearing loss (SNHL); other sequelae include intellectual disability, cerebral palsy, visual impairment, and seizures.^{3,4} This clinical practice guideline reviews the epidemiology, diagnosis, and prevention of CMV infection during pregnancy, and the pathogenesis and management of fetal CMV infection.

While this guideline does not make recommendations for the care of infants with sequelae of cCMV, it does highlight recent evidence supporting cCMV screening and treatment for newborns. We address the fact that a proportion of cCMV-related disability can be modified, to some extent, through neonatal diagnosis and intervention, combined with Canada's well-established services for early hearing detection and intervention.

EPIDEMIOLOGY OF MATERNAL AND CONGENITAL CMV INFECTIONS

CMV seroprevalence in patients of child-bearing age, defined as evidence of previous CMV infection (positive CMV immunoglobulin G [IgG]), is estimated to be 40% to 54% in Canada.^{5,6} Seroprevalence is higher among patients born in low-resource settings and those with current or past sexually transmitted infections; seroprevalence increases with age and parity.^{7,8} CMV seroprevalence is also higher in patients who are exposed to young children, such as daycare workers.^{6,9} Rates of cCMV in neonates increase with higher seroprevalence in mothers.^{10,11,12}

ABBREVIATIONS

CMV	cytomegalovirus
cCMV	congenital cytomegalovirus infection
CVS	chorionic villus sampling
ELISA	enzyme-linked immunosorbent assay
IUGR	intra uterine growth restriction
IgG	immunoglobulin G
IgM	immunoglobulin M
PCR	polymerase chain reaction
SGA	small for gestational age

Primary maternal CMV infection affects approximately 2% of pregnancies and is associated with the same factors driving CMV seroprevalence in patients of child-bearing age, mentioned above.^{13,14,15} In particular, there is a higher risk of primary maternal CMV infection^{16,17} if the interval between the mother's pregnancies is less than 3 years, as younger infants excrete CMV more frequently and increase the risk of the mother acquiring the infection.^{18,19,20} Primary maternal infection during pregnancy carries a risk of cCMV of 30% to 40%. This risk, and the risk of associated sequelae, depend on the gestational age at which the mother acquires the infection^{11,15,21,22} (Figure 2). In general, the likelihood of CMV transmission to the fetus increases proportionally with the gestational age at which the mother acquires the infection. However, the risk of long-term sequelae for the infant is inversely proportional to the gestational age at which cCMV is acquired.^{23,24} Recent data suggest that exposure to CMV only in the first trimester of pregnancy is associated with sequelae in children at 2 years of age.²²

Data show that intrauterine transmission of CMV occurs in 0.5% to 1.5% of pregnant patients with evidence of pre-conception immunity (non-primary infections).^{11,25,26} The severity of cCMV due to non-primary maternal infection appears to be similar to that resulting from primary maternal infections.^{3,10,12,27,28,29,30} Importantly, in regions with low seroprevalence, such as Canada, it is estimated that half of cCMV infections are due to non-primary maternal infections.^{10,12,25,29,31}

PATHOGENESIS AND CLINICAL MANIFESTATIONS OF MATERNAL AND CONGENITAL CMV INFECTIONS


Primary CMV Infection

CMV is typically transmitted person-to-person through close contact with infectious virus shed in saliva, urine, genital secretions, and other body fluids; blood transfusion and organ transplantation are also recognized routes of infection. Primary CMV infection during pregnancy is asymptomatic in 95% of cases.³² When CMV infection is symptomatic, the clinical presentation is the same as that in non-pregnant individuals. The incubation period ranges from 20 to 60 days, after which a mild mononucleosis-like syndrome ensues, with fever lasting 2 to 3 weeks, lymphadenopathy, high lymphocyte count, and abnormal liver enzyme results. Rare complications include hepatitis, Guillain-Barré syndrome, and myocarditis.³³

Non-Primary CMV Infection


Non-primary CMV infection results from either reactivation of endogenous (latent) virus or re-infection by

Figure 1. Estimated congenital CMV infection burden in Canada. Rate 0.42% (1 in 240), extrapolated from Larke et al. (1980), for the city of Hamilton, Ontario



Canada 2017: approximately 250 to 334 babies affected by CMV-related disability.

Figure 2. Risk of fetal infection and risk of long-term infant sequelae in relation to gestational age



SOURCE: Adapted from Hutchinson BJ, Palma-Dias R, Walker SP. Universal cytomegalovirus screening: Time for reappraisal? *Fetal and Maternal Medicine Review*. 2014;25. Available from: <https://www.cambridge.org/core/journals/fetal-and-maternal-medicine-review/article/universal-cytomegalovirus-screening-time-for-reappraisal/1A33E7C055351C2BB6AABA71D117C18E>

exogenous virus.^{34,35,36} Even in healthy individuals, CMV may periodically reactivate from latency, shedding at mucosal surfaces during reactivation.³²

Congenital CMV Infection

cCMV refers to mother-to-child transmission of CMV in utero (transplacentally) that is present at birth, as determined by its presence in neonatal urine, blood, or saliva in the first 21 days of life.³⁷ cCMV can manifest in utero as intrauterine growth restriction, fetal hepatosplenomegaly, and intracranial white matter changes and calcifications,

which are progressive over the gestation and depending on when the infection occurred.³²

CMV can also be transmitted from mother to child through exposure to CMV-infected maternal blood or genital secretions during birth or, most commonly, through breastfeeding after birth. This is called postnatal infection and is more common than congenital infection.³⁸

Postnatal infection is not associated with adverse infant outcomes, except among very-low-birthweight infants, who may present with end-organ disease and a sepsis-like

syndrome,³² may develop chronic lung disease, and may have neurocognitive sequelae. However, the risk of long-term effects remains controversial.^{39,40} Therefore, breastfeeding is considered safe in patients with CMV infection during pregnancy.

DIAGNOSIS OF CMV INFECTION

Maternal Infection: Diagnosis

Women should be tested for CMV infection during pregnancy if there are fetal ultrasound abnormalities suggestive of cCMV,^{41,42} or if pregnant patients have symptoms of CMV, including generalized illness (i.e., a mononucleosis-like syndrome) and undifferentiated hepatitis.³³

See Figure 3 for the recommended approach to testing for CMV infection during pregnancy. Currently available serologic tests are difficult to interpret; it is not always possible to determine when the maternal infection was acquired (see Table 1 for interpretation of serologic test results). The gold standard for diagnosing primary CMV infection is the documentation of a positive CMV IgG result in a person with previous documentation of a negative test result (seroconversion).^{43,44} When a patient’s previous immune status is unavailable, a combination of testing for


CMV immunoglobulin M (IgM), CMV IgG, and CMV IgG avidity (where available) is recommended.

A positive result of a maternal CMV IgM test requires cautious interpretation because CMV IgM titres can be high for 1 to 3 months following a primary CMV infection⁴⁴ and can persist at low levels for 12 to 18 months following primary infection.⁴⁵ This makes it difficult to determine when the infection was acquired based solely on IgM presence. As well, CMV IgM levels can increase because of a non-primary infection.^{44,46}

Furthermore, a negative result of maternal CMV IgM test does not rule out cCMV, as illustrated by a study of pregnancies in which fetal infection was confirmed following sonographic markers of congenital CMV infection. Among cases with a positive result of CMV on polymerase chain reaction (PCR) testing of amniotic fluid, the CMV IgM result was negative in 56%.⁴¹ All of these infections were detected in either the second or third trimester. This evidence indicates either early first-trimester primary infection, as sonographic evidence of fetal infection takes several weeks to appear,⁴² or non-primary infection.

CMV IgG avidity, the measure of how strongly IgG binds to CMV antigens, can help determine when the primary

Figure 3. Algorithm for approach to maternal CMV serologic testing during pregnancy



^a At least 8 weeks after presumed infection.

^b cCMV is defined as + CMV PCR amniotic fluid and/or + CMV PCR newborn urine, blood, or saliva.

Table 1. Interpretation of maternal cytomegalovirus (CMV) serologic tests

CMV serologic test result	CMV IgG avidity result	Interpretation	Implications
CMV IgM negative CMV IgG negative	N/A	Two possibilities: No evidence of infection Very early infection	Counsel patient concerning prevention of CMV acquisition during pregnancy Consider repeating in 4 weeks according to clinical situation
CMV IgM positive CMV IgG negative	N/A	Two possibilities: 1 Primary Infection 2 False-positive IgM result due to other infections, autoimmune disease, or laboratory methods ^a	Repeat in 4 weeks Test stored serum, if available
CMV IgM positive CMV IgG positive	Low ^b	Recent CMV infection	Test stored serum, if available, especially if avidity is unavailable: Seroconversion (negative CMV IgG in the past) is diagnostic of primary infection Counsel patient concerning risk of fetal infection and sequelae, and options for prenatal diagnosis (amniocentesis) and/or neonatal testing
CMV IgM positive CMV IgG positive	High ^b	Two possibilities: Past infection ^a Recent non-primary infection, if CMV IgG titres are rising	If sonographic anomalies are suggestive of cCMV, <ul style="list-style-type: none"> • Test stored serum, if available: A several-fold^c rise of CMV IgG titres compared with stored sample or on serial samples performed with the same kit is suggestive of recent non-primary infection • Counsel patient concerning risk of fetal infection and possible sequelae, and options for prenatal diagnosis (amniocentesis) and/or neonatal testing
CMV IgM negative CMV IgG positive	High ^b	Two possibilities: Past infection Recent non-primary infection if CMV IgG titres are rising	If sonographic anomalies are suggestive of cCMV, <ul style="list-style-type: none"> • Test stored serum if available: A several-fold^c rise of CMV IgG titre compared with prior sample or on serial samples performed with the same kit is indicative of recent non-primary infection • Counsel patient concerning low risk of fetal infection and possible sequelae and/or neonatal testing
CMV IgM negative CMV IgG positive	Low ^b	Unclear significance	Suggest consultation with specialist

^a IgM can remain positive for up to 18 months.

^b If unavailable, test stored serum sample taken preconception or in early pregnancy.

^c Traditionally, a 4-fold increase has been considered suggestive of recent infection, but this can vary according to the test used. Consult a local virologist regarding assay performance.

cCMV: congenital cytomegalovirus infection; IgG: immunoglobulin G; IgM: immunoglobulin M; N/A: not applicable.

infection was acquired and should be performed primarily in cases where IgG and IgM are positive, or considered when IgM is negative and IgG is positive but there are concerning clinical features for congenital CMV infection (e.g., abnormal ultrasound findings). IgG avidity is low in early

CMV infections, becoming high 5 to 6 months following primary infection.^{47,48} In addition to levels “high” and “low,” avidity is referred to as “indeterminate” at a transition from low to high. However, there are some diagnostic dilemmas with avidity testing as well. Low levels of IgG in

the sample can result in falsely low avidity levels.⁴⁹ As of November 2020, avidity testing is available in 3 Canadian provinces: Ontario, Québec, and Alberta.

Patients in the second trimester or later with sonographic findings suggestive of cCMV and low avidity should be offered further amniocentesis and/or newborn testing (See Box); these findings may indicate an infection acquired or reactivated during early pregnancy.^{47,50,51,52} CMV PCR testing of maternal urine is not part of routine testing for CMV infection during pregnancy and should be reserved to specialists in maternal–fetal medicine, reproductive infectious diseases, and infectious diseases.

RECOMMENDATIONS 1, 2, 3, and 4

Fetal Infection: Diagnosis and Prognosis of Fetal Infection

Abnormal fetal sonographic findings (Box) are a common indication for testing for cCMV.⁵² However, these findings are not specific for cCMV. Further, sonography is not a sensitive diagnostic tool, as less than of 50% of fetal infections exhibit findings on sonography.^{42,53} Even when there are abnormal sonographic findings, there may be a delay before they are seen.⁴²

The gold standard for diagnosing in utero cCMV infection is a positive result of a CMV PCR test of amniotic fluid obtained by amniocentesis.^{52,54} The sensitivity and negative predictive value of a negative PCR result of amniotic fluid is 93%;⁴⁴ the specificity of a positive amniotic fluid PCR result for cCMV is 100%.

Timing of amniocentesis is important; traditionally, it has been recommended after 21 weeks gestation and at least 6 weeks after suspected maternal infection.^{52,55,56} In a recent

study by Enders et al., there was no difference in sensitivity in amniocentesis-based testing performed at 17 weeks or at 20 weeks gestation, as long as at least 8 weeks had elapsed after suspected maternal infection.⁵⁷ cCMV-related fetal abnormalities, especially the central nervous system findings, can evolve, and fetal sonography and magnetic resonance imaging (MRI) have been used to predict neurologic impairment, with inconsistent results.^{58,59,60,61} Abnormal fetal sonographic and MRI findings may be seen in children with normal outcomes. However, consistently normal fetal sonographic and MRI findings confer a low risk of long-term neurologic deficits. A normal third-trimester fetal MRI has been reported to have a high negative predictive value for SNHL.⁶²

Viral load in amniotic fluid has been investigated as a potential marker for predicting neonatal outcomes, with conflicting results.^{50,63,64} Some studies have found an association between higher viral loads and the severity of the disease, while others have not. Ultimately, studies have not consistently shown that low levels or even negative amniotic fluid PCR results rule out neurologic impairment or SNHL.^{65,66}

RECOMMENDATION 5

SUMMARY

Diagnosis of both maternal CMV infection and cCMV can be challenging, and involving experts in this area, through a multidisciplinary team approach, is recommended. Ideally, if stored sera are available, maternal infection can be documented by demonstrating seroconversion. If this is not possible, maternal testing for IgM, IgG, and IgG avidity (where available) is recommended. Sonographic findings may suggest cCMV, but are not specific for this diagnosis. Fetal infection is documented by positive CMV

Box. Common sonographic findings in congenital cytomegalovirus infection

Central nervous system	Cardiac	Abdominal	Placenta	Other
<ul style="list-style-type: none"> • Ventriculomegaly • Calcifications • Microcephaly • Subependymal/periventricular cysts • Periventricular hyperechogenicity • Cerebellar aplasia • Porencephaly • Lissencephaly 	<ul style="list-style-type: none"> • Cardiomegaly • Pericardial effusion • Calcifications 	<ul style="list-style-type: none"> • Hepatomegaly • Splenomegaly • Calcifications • Ascites • Echogenic bowel 	<ul style="list-style-type: none"> • Placentomegaly • Small placenta • Oligohydramnios 	<ul style="list-style-type: none"> • Intrauterine growth restriction • Death • Pelvic cysts

SOURCE: Adapted from Society for Maternal-Fetal Medicine, Hughes BL, Gyamfi-Bannerman C. Diagnosis and antenatal management of congenital cytomegalovirus infection. *Am J Obstet Gynecol.* 2016;214:B5-B11. Available from: <https://pubmed.ncbi.nlm.nih.gov/26902990/>

PCR results from amniotic fluid. See [Figure 3](#) for algorithms to assist with the approach to maternal serologic testing and sonographic findings.

PREVENTION OF MATERNAL CMV INFECTION DURING PREGNANCY

Ultimately, the best strategy to prevent cCMV would be an effective vaccine against CMV. While there is optimism that such a vaccine will be developed, current candidates are still in early-phase trials.⁶⁷ One randomized, double-blinded, placebo-controlled trial showed promising results, with a significantly lower infection rate among patients who received the vaccine (8% in the vaccine group compared with 14% in the placebo group, $P = 0.02$).⁶⁸ Until a safe and effective CMV vaccine is clinically available, primary prevention of cCMV relies on patient education and hygiene measures.

Studies conducted in North America and Europe have repeatedly demonstrated that awareness of cCMV among the general population and pregnant patients is low, and that behaviour that raises the risk of maternal CMV acquisition is common. Two studies have demonstrated that pregnant and postpartum patients are less aware of cCMV than they are of other congenitally acquired infections.^{69,70} In Canada, only 15% to 25% of pregnant patients report awareness of CMV and its implications for pregnancy,⁵ but once informed, 74% want CMV screening in pregnancy.⁷¹

Similarly, awareness of and counselling about cCMV remain low among perinatal care providers.^{72,73} A 2012 study of 800 perinatal care providers in France identified knowledge gaps, particularly regarding the mode of transmission of CMV and the availability of effective in utero therapy. In the Netherlands, 41% of 330 midwives reported never informing a patient about CMV, and midwives cited that the most common reason for avoiding this discussion was that they did not have enough information.^{70,72,73}

Results from several studies, including 1 randomized controlled trial, provide evidence that education about hygiene measures may be an effective means of reducing the incidence of primary CMV infection among patients who are seronegative.^{74,75,76,77} Studies considering whether such interventions could be effective for pregnant patients more broadly, (i.e., regardless of their serologic status) are sparse. Price et al. carried out a web-intervention for 809 patients of reproductive age in the U.S., in which participants completed surveys before and after they either read a fact sheet or viewed an educational video.⁷⁸ Both the fact sheet and the video increased knowledge and acceptance of behavioural

interventions. Seventy-two percent of patients reported motivation to adopt these behaviours after either intervention (fact sheet or video). In this study, obstetricians and pediatricians were the most frequently mentioned “preferred channels” for communicating information about CMV. Thackeray et al. conducted a study to characterize further the acceptability of behavioural measures among patients in the U.S. who were of reproductive age and had young children at home.^{79,80} They randomly assigned 840 patients to read 1 of 4 CMV fact sheets and complete and questionnaires about knowledge and intended behaviours before and after reading. The authors found that, while most patients adopted positive attitudes toward protective behaviours, the least favoured behaviours were avoiding kissing on the lips and avoiding sharing food.⁷⁹

There is evidence that educational interventions to promote hygiene measures may reduce primary CMV acquisition during pregnancy. However, most data come from studies involving patients who are aware of their susceptibility to primary CMV during pregnancy, which may be an essential motivator to adopt hygiene measures. Given the importance of non-primary maternal infection for cCMV,^{10,12,25,29,31} more data are needed to assess the impact of educational interventions to prevent cCMV in seropositive patients. However, preventive measures effective against primary infection are likely to reduce reinfection as well. As these education and hygienic interventions are inexpensive and straightforward, they should be considered for all pregnant patients, regardless of serologic status.

Although CMV seroprevalence is higher in daycare workers than in the general population, reliable data is lacking regarding their risk of CMV primary infection. CMV seroprevalence and primary CMV infection incidence are not increased among health care workers. Therefore, we do not recommend that pregnant patients who are working with children younger than 3 years of age take time off work. Instead, we recommend that any worker who is pregnant or who may become pregnant and works with children younger than 3 years of age be provided with education regarding strategies to prevent CMV acquisition.⁸¹

RECOMMENDATION 6

PRENATAL TREATMENT AND PREVENTION OF FETAL INFECTION

Despite advances in the diagnosis of fetal CMV infection, treatment options during pregnancy remain limited. Both oral valacyclovir and CMV-specific hyperimmune globulin

(CMV-HIG) have been studied to prevent fetal CMV infection (i.e., mother-to-child transmission) or treat established fetal infection. Studies have included only primary maternal CMV infections.

Maternal Antiviral Therapy to Treat or Prevent Congenital CMV Infection

Valacyclovir appears safe for use in pregnancy, even in the first trimester.^{82,83} At a dosage of 8 g per day, it results in therapeutic concentrations in amniotic fluid and fetal blood.⁸⁴

However, the available evidence is insufficient to recommend routine maternal antiviral therapy for fetal infection. A recent double-blind, randomized controlled trial reported on 90 pregnant patients with primary CMV infection acquired during the periconceptional period or the first trimester of pregnancy. Patients were randomly assigned to receive either oral valacyclovir (8 g per day) or placebo. Fetal infection rates determined by CMV PCR of amniotic fluid were 29.8% in the placebo group and 11.1% in valacyclovir group (OR 0.29; 95% CI 0.09–0.9)⁸⁵ The benefit was limited to those with infection acquired during the first trimester; there was no significant difference in fetal infection among patients with periconceptional infection. While the results of this small, single-centre study are highly suggestive of valacyclovir's efficacy in preventing cCMV among patients with first-trimester primary infection, they need to be replicated in other trials. Two prior studies looking at antiviral medications to prevent cCMV-associated sequelae among pregnancies with confirmed cCMV showed conflicting results. One documented less likelihood of symptomatic disease at birth among infants whose mothers were treated during pregnancy, but the other found no difference.^{86,87}

Maternal CMV-HIG Immunotherapy to Treat or Prevent Congenital CMV Infection

Seven studies, including 2 randomized controlled trials, have reported on the use of CMV-HIG among pregnant patients with primary CMV infection and without evidence of fetal infection (amniocentesis either not done or results negative for CMV) to prevent cCMV (Table 2).^{88,89,90,91,92,93,94} Following earlier studies with inconsistent results, a recent, high-quality, multi-centre, double-blind randomized placebo-controlled trial found CMV-HIG ineffective in decreasing the risk of cCMV or fetal death among patients with primary CMV infection in early pregnancy. The trial was stopped early at the recommendation of the study's data and safety monitoring committee.

Nine studies have reported on fetal outcomes after CMV-HIG treatment during pregnancies with fetal infection confirmed by amniocentesis (Table 3).^{88,89,91,92,95,96,97,98,99} The findings,

taken as a whole, show a trend toward decreased morbidity for fetuses whose mothers received CMV-HIG, even though there were no statistically significant differences.

Overall, among pregnant patients with first-trimester primary CMV infections, there are limited data to support the use of valacyclovir 8 g per day for the prevention of fetal CMV infection, and high-quality evidence to recommend against use of CMV-HIG for the same purpose.

For established cCMV infections during pregnancy, the available evidence is insufficient to recommend using either CMV-HIG or antiviral medications to reduce sequelae in infected fetuses. These therapies should be used only by experienced teams after appropriate counselling, ensuring active patient participation in the decision-making process.

RECOMMENDATIONS 7, 8, and 9

Counselling of Patients with a Prior Pregnancy Resulting in Congenital CMV Infection

There are no data on pregnancy and infant outcomes in subsequent pregnancies following a pregnancy affected by cCMV. Although affected patients have CMV-specific immunity, they can still acquire a CMV infection and transmit the infection to their fetuses,^{11,25,26} and this congenital infection can result in sequelae comparable to those arising from primary infections.^{3,10,12,27,28,29,30} The crucial point to convey to these pregnant patients is that their risk of cCMV (given pre-conception immunity) is far lower, at 0.5% to 1.5%, compared with primary infections.^{11,25,26}

In this context, educating these women on hygiene measures is critical (see Prevention of Maternal CMV Infection During Pregnancy), and maternal serologic testing is not helpful (Table 1).

Screening for Maternal CMV Serologic Status

Screening for maternal CMV serologic status in pregnancy is controversial, because of the absence of reproducible and readily interpretable diagnostic tests, and because non-primary CMV maternal infections pose a risk of cCMV similar to that of primary infections.

However, there are several points to consider. Congenital CMV acquired during the first trimester is associated with the highest risk of long-term neurodevelopmental sequelae. Given the relatively low seroprevalence of CMV in Canada, primary infections contribute to half of the cases of cCMV. Limited but good-quality data support the use of valacyclovir to prevent cCMV infection resulting from primary

Table 2. Published literature on cytomegalovirus-specific hyperimmune globulin (CMV-HIG) for prevention of congenital CMV infection (cCMV)

Author, year of publication	Country	Methods	Intravenous HIG group	Control group	Rate of cCMV (% HIG / % control)
Nigro et al., 2005 ⁸⁸	Italy	Prospective cohort	n = 37 monthly 100 UI/kg	n = 47	16% / 40% ($P = 0.02$)
Buxmann et al., 2012 ⁸⁹	Germany	Case series	n = 37 (1 twin pregnancy) 200 UI/kg	None	24% in the HIG group
Revello et al., 2014 ⁹⁰	Italy	Randomized double-blind trial	n = 61 monthly Cytotect 100 UI/kg	n = 62 Placebo	30% / 44% ($P = 0.130$)
Minsart et al., 2018 ⁹¹	Canada	Retrospective cohort	n = 5 monthly Cytogam 150 mg/kg	n = 26	20% / 38.5% ($P = 0.631$)
Blazquez-Gamero et al., 2019 ⁹²	Spain	Retrospective cohort	n = 17 monthly Cytotect 100 UI/kg	None	41%
Kagan et al., 2019 ⁹³	Belgium Germany	Prospective cohort / historical controls	n = 40 biweekly Cytotect 200 UI/kg before 14 weeks	n = 108	7.5% / 35.2% ($P < 0.0001$)
Hughes, 2019 ⁹⁴	USA	Randomized double-blind trial	n = 206 monthly Cytogam 100 UI/kg	n = 193	22.7% / 19.4% ($P = 0.424$)

maternal CMV infections in the first trimester⁸⁵ (see Prenatal Treatment and Prevention of Fetal Infection for a detailed discussion).

Pregnant patients, especially those at high risk of CMV primary infection (patients in contact with children 3 years old and younger) can be offered CMV serologic testing in the first trimester to screen for CMV primary infection. Importantly, pregnant patients with positive results of serologic testing remain at risk for cCMV in their fetus. A message that such patients are “CMV-immune” could be misleading and provide false reassurance. Rather, CMV prevention strategies should be discussed with all patients, regardless of their serologic status, to reduce the risk of cCMV through maternal infection or reinfection during pregnancy.

The cost-effectiveness of CMV screening strategies during pregnancy needs to be further evaluated.

RECOMMENDATION 10

POSTNATAL MANAGEMENT OF CONGENITAL CMV INFECTION

A detailed discussion of the care of infants with cCMV is outside the scope of this guideline. However, it is noteworthy that there is level I evidence for the benefit of antiviral treatment

for selected infants with symptomatic cCMV,^{100,101} which is now the standard of care.^{37,43} Furthermore, early diagnosis of cCMV appears to be beneficial, even in the absence of medical treatment, as it allows for appropriate monitoring and support for hearing loss and developmental delay.^{37,102,103} CMV testing of newborns who fail the newborn hearing screen (i.e., targeted screening) has become widely adopted,^{104,105} including at some Canadian centres. The province of Ontario added CMV to the universal newborn screening panel in 2019, as an adjunct to its well-established newborn hearing screening program. However, targeted CMV screening still misses over half of all infants with cCMV who develop SNHL after birth.¹⁰⁶ It is estimated to be substantially less cost-effective than universal newborn CMV screening, which could identify all infected newborns, allowing for early intervention and appropriate anticipatory guidance.^{102,103} Management of infants with cCMV requires a multidisciplinary approach and should be undertaken in consultation with an expert in pediatric infectious diseases.^{37,105}

CONCLUSIONS

CMV is the most common congenital infection. Even though most infants born with congenital CMV infection are healthy at birth, approximately 1 in 5 to 6 will suffer permanent neurologic sequelae like hearing loss. Simple strategies can prevent its acquisition. Therefore, we recommend raising awareness of CMV among all patients of

Table 3. Published literature on cytomegalovirus-specific hyperimmune globulin (CMV-HIG) for prevention of congenital CMV infection – associated sequelae

Author, year of publication	Country	Methods	Intervention	Symptoms at birth (% HIG / % control)	Adverse neurodevelopmental outcome (% HIG / % control)
Nigro et al., 2005 ⁸⁸	Italy	Prospective cohort n = 31 HIG n = 14 no treatment	IV HIG (200 UI/kg), repeated + HIG intra-umbilical-cord or intra-amniotic infusion if persistent sonographic signs	3% / 50% (<i>P</i> = 0.001)	3% / 42% (+ 2 perinatal death)
Nigro et al., 2008 ⁹⁵	Italy	Case series n = 3 HIG n = 2 no treatment	IV HIG (Cytotect, 200 UI/kg) every 2 to 3 weeks + intra-amniotic HIG infusion	0% / 100%	0% / 100%
Nigro et al., 2012 ^{98,a}	Italy	Case series n = 8 HIG n = 8 no HIG	IV HIG (Cytotect, 200 UI/kg) repeated if persistent sonographic signs	12% / 100%	12% / 100% (<i>P</i> < 0.0004)
Visentin et al., 2012 ⁹⁷	Italy	Prospective cohort n = 31 HIG n = 36 no HIG	IV HIG (Cytotect, 200 UI/kg) once	Unknown	13% / 43% (<i>P</i> < 0.01)
Buxmann et al., 2012 ⁸⁹	Germany	Retrospective case series n = 3 ^b	IV HIG + fetal intra-umbilical cord or intra-amniotic HIG infusion	0%	100% normal at 1 year old
Japanese Congenital Cytomegalovirus Infection Immunoglobulin Fetal Therapy Study Group 2012 ⁹⁹	Japan	Prospective case series n = 5 ^c	Weekly IV HIG (7.5–15.0 g) and/or HIG injection into the fetal peritoneal cavity	80%	20% (+ 1 early neonatal death)
Nigro et al., 2012 ⁹⁶	Italy	Case-control	IV CMV HIG every 2 to 4 weeks (200 UI/kg)		32 cases: hearing deficit and/or neurodevelopmental sequelae 32 controls: no sequelae, matched for timing of CMV infection and age at the last evaluation Cases more likely to be born of patients not treated with CMV-HIG during pregnancy (87.5% vs. 15.6%, <i>P</i> < 0.0001)
Minsart et al., 2018 ⁹¹	Canada	Retrospective cohort n = 11 HIG n = 29 no HIG	Monthly IV CMV HIG (Cytogam 150 mg/kg)	72.7% / 34.5% (<i>P</i> = 0.003)	45.5% / 17.2% (<i>P</i> = 0.103)
Blazquez-Gamero et al., 2019 ⁹²	Spain	Retrospective cohort n = 19	IV HIG (Cytotect 200 UI/kg) repeated once if abnormal sonographic signs	50%	20% ^d

^a Nine of these 16 patients were included in previous publications.

^b Cases without IV HIG (fetal intra-umbilical or intra-amniotic HIG infusion only) are not included.

^c Cases without IV HIG (fetal intra-umbilical or intra-amniotic HIG infusion only) are not included.

^d Three cases were lost to follow-up.

IV: intravenous.

child-bearing age and perinatal health care providers. We involved patients’ voices in the development of these guidelines, and our patient partners urged us to make

awareness of preventive strategies a high priority. Serologic tests to diagnose CMV infection in pregnancy require cautious interpretation. When primary CMV infection during

pregnancy or cCMV is suspected, a referral to a maternal–fetal medicine and/or a reproductive infectious disease specialist is warranted. Early diagnosis of cCMV appears to be beneficial, as it allows for assessment of treatment eligibility as well as appropriate monitoring and support for hearing loss and developmental delay.

GUIDELINE TOOLKIT

SOGC members can visit the Guideline Resource Kit webpage on sogc.org to find complementary tools and resources and to participate in accredited continuing professional development activities.

SUPPLEMENTARY MATERIAL

Supplementary data related to this article can be found at <https://doi.org/10.1016/j.jogc.2021.05.015>.

REFERENCES

- Embil JA, Macdonald JM, Scott KE. Survey of a neonatal population for the prevalence of cytomegalovirus. *Scand J Infect Dis* 1975;7:165–7. Available at <https://www.ncbi.nlm.nih.gov/pubmed/170671>.
- Larke RP, Wheatley E, Saigal S, et al. Congenital cytomegalovirus infection in an urban canadian community. *J Infect Dis* 1980;142:647–53. Available at <https://www.ncbi.nlm.nih.gov/pubmed/6257793>.
- Townsend CL, Forsgren M, Ahlfors K, et al. Long-term outcomes of congenital cytomegalovirus infection in sweden and the united kingdom. *Clin Infect Dis* 2013;56:1232–9. Available at <https://www.ncbi.nlm.nih.gov/pubmed/23334811>.
- Korndewal MJ, Oudesluis-Murphy AM, Kroes ACM, et al. Long-term impairment attributable to congenital cytomegalovirus infection: A retrospective cohort study. *Dev Med Child Neurol* 2017;59:1261–8. Available at <https://www.ncbi.nlm.nih.gov/pubmed/28990181>.
- Wizman S, Lamarre V, Coic L, et al. Awareness of cytomegalovirus and risk factors for susceptibility among pregnant women, in montreal, canada. *BMC Pregnancy Childbirth* 2016;16:54. Available at <https://www.ncbi.nlm.nih.gov/pubmed/26979058>.
- Vaudry W, Rosychuk RJ, Lee BE, et al. Congenital cytomegalovirus infection in high-risk canadian infants: Report of a pilot screening study. *Can J Infect Dis Med Microbiol* 2010;21:e12–9. Available at <https://www.ncbi.nlm.nih.gov/pubmed/21358874>.
- Kakkar F, Renaud C, Valois S, et al. Implementation of a cmv screening program for infants of hiv infected mothers by salivary pcr and/or culture: Results from a single center. *Canadian Journal of Infectious Diseases and Medical Microbiology* 2015;SB:72B.
- Bate SL, Dollard SC, Cannon MJ. Cytomegalovirus seroprevalence in the united states: The national health and nutrition examination surveys, 1988–2004. *Clin Infect Dis* 2010;50:1439–47. Available at <https://www.ncbi.nlm.nih.gov/pubmed/20426575>.
- N'Diaye DS, Yazdanpanah Y, Krivine A, et al. Predictive factors of cytomegalovirus seropositivity among pregnant women in paris, france. *PLoS One* 2014;9:e89857. Available at <https://www.ncbi.nlm.nih.gov/pubmed/24587077>.
- Britt WJ. Congenital human cytomegalovirus infection and the enigma of maternal immunity. *J Virol* 2017;91. Available at <https://www.ncbi.nlm.nih.gov/pubmed/28490582>.
- Kenneson A, Cannon MJ. Review and meta-analysis of the epidemiology of congenital cytomegalovirus (cmv) infection. *Rev Med Virol* 2007;17:253–76. Available at <https://www.ncbi.nlm.nih.gov/pubmed/17579921>.
- de Vries JJ, van Zwet EW, Dekker FW, et al. The apparent paradox of maternal seropositivity as a risk factor for congenital cytomegalovirus infection: A population-based prediction model. *Rev Med Virol* 2013;23:241–9. Available at <https://www.ncbi.nlm.nih.gov/pubmed/23559569>.
- Lamarre V, Gilbert NL, Rousseau C, et al. Seroconversion for cytomegalovirus infection in a cohort of pregnant women in quebec, 2010–2013. *Epidemiol Infect* 2016;144:1701–9. Available at <https://www.ncbi.nlm.nih.gov/pubmed/26686548>.
- Hyde TB, Schmid DS, Cannon MJ. Cytomegalovirus seroconversion rates and risk factors: Implications for congenital cmv. *Rev Med Virol* 2010;20:311–26. Available at <https://www.ncbi.nlm.nih.gov/pubmed/20645278>.
- Stagno S, Pass RF, Cloud G, et al. Primary cytomegalovirus infection in pregnancy. Incidence, transmission to fetus, and clinical outcome. *JAMA* 1986;256:1904–8. Available at <https://www.ncbi.nlm.nih.gov/pubmed/3020264>.
- Leruez-Ville M, Guilleminot T, Stirnemann J, et al. Quantifying the burden of congenital cytomegalovirus infection with long-term sequelae in subsequent pregnancies of women seronegative at their first pregnancy. *Clin Infect Dis* 2020;71:1598–603.
- Leruez-Ville M, Guilleminot T, Stirnemann J, et al. Quantifying the burden of congenital cytomegalovirus infection with long-term sequelae in subsequent pregnancies of women seronegative at their first pregnancy. *Clinical Infectious Diseases* 2019;71:1598–603. <https://doi.org/10.1093/cid/ciz1067>. Available at.
- Murph JR, Baron JC, Brown CK, et al. The occupational risk of cytomegalovirus infection among day-care providers. *JAMA* 1991;265:603–8. <https://doi.org/10.1001/jama.1991.03460050057020>. Available at.
- Adler SP. Molecular epidemiology of cytomegalovirus: Viral transmission among children attending a day care center, their parents, and caretakers. *The Journal of Pediatrics* 1988;112:366–72. Available at <http://www.sciencedirect.com/science/article/pii/S0022347688803147>.
- Pass RF, Hutto C, Ricks R, et al. Increased rate of cytomegalovirus infection among parents of children attending day-care centers. *N Engl J Med* 1986;314:1414–8.
- Enders G, Daiminger A, Bader U, et al. Intrauterine transmission and clinical outcome of 248 pregnancies with primary cytomegalovirus infection in relation to gestational age. *J Clin Virol* 2011;52:244–6. Available at <https://www.ncbi.nlm.nih.gov/pubmed/21820954>.
- Faure-Bardon V, Magny JF, Parodi M, et al. Sequelae of congenital cytomegalovirus (cmv) following maternal primary infection are limited to those acquired in the first trimester of pregnancy. *Clin Infect Dis* 2018. Available at <https://www.ncbi.nlm.nih.gov/pubmed/30596974>.
- Hutchinson BJ, Palma-Dias R, Walker SP. Universal cytomegalovirus screening: Time for reappraisal? *Fetal and Maternal Medicine Review* 2014;25:117–33. Available at <https://www.cambridge.org/core/article/universal-cytomegalovirus-screening-time-for-reappraisal/1A33E7C055351C2BB6AABA71D117C18E>.
- Hutchinson BJ, Palma-Dias R, Walker SP. Universal cytomegalovirus screening: Time for reappraisal? *Fetal and Maternal Medicine Review* 2014;25. Available at <https://www.cambridge.org/core/journals/fetal->

- and-maternal-medicine-review/article/universal-cytomegalovirus-screening-time-for-reappraisal/1A33E7C055351C2BB6AABA71D117C18E.
25. Papaevangelou V, Christoni Z, Vliora C, et al. Neonatal screening for congenital cmv infection stresses the importance of maternal nonprimary infection even in an area where prenatal serology testing is common. *J Matern Fetal Neonatal Med* 2017;1–4. Available at <https://www.tandfonline.com/doi/full/10.1080/14767058.2017.1416605>.
 26. Mussi-Pinhata MM, Yamamoto AY, Aragon DC, et al. Seroconversion for cytomegalovirus infection during pregnancy and fetal infection in a highly seropositive population: "The brachs study". *J Infect Dis* 2018;218:1200–4. Available at <https://www.ncbi.nlm.nih.gov/pubmed/29868783>.
 27. Ross SA, Fowler KB, Ashrith G, et al. Hearing loss in children with congenital cytomegalovirus infection born to mothers with preexisting immunity. *J Pediatr* 2006;148:332–6. Available at <https://www.ncbi.nlm.nih.gov/pubmed/16615962>.
 28. Dreher AM, Arora N, Fowler KB, et al. Spectrum of disease and outcome in children with symptomatic congenital cytomegalovirus infection. *J Pediatr* 2014;164:855–9. Available at <https://www.ncbi.nlm.nih.gov/pubmed/24433826>.
 29. Puhakka L, Renko M, Helminen M, et al. Primary versus non-primary maternal cytomegalovirus infection as a cause of symptomatic congenital infection - register-based study from finland. *Infect Dis (Lond)* 2017;49:445–53. Available at <https://www.ncbi.nlm.nih.gov/pubmed/28116961>.
 30. Britt WJ. Maternal immunity and the natural history of congenital human cytomegalovirus infection. *Viruses* 2018;10.
 31. Ahlfors K, Ivarsson SA, Harris S. Report on a long-term study of maternal and congenital cytomegalovirus infection in sweden. Review of prospective studies available in the literature. *Scand J Infect Dis* 1999;31:443–57. Available at <https://www.ncbi.nlm.nih.gov/pubmed/10576123>.
 32. Britt W. Chapter 24: Cytomegalovirus. In: Wilson CB, editor. *Remington and klein's infectious diseases of the fetus and newborn infant*. 8th ed. Philadelphia, Pennsylvania: Elsevier Saunders; 2016. p. 724–81.
 33. Crumpacker CS. Chapter 140: Cytomegalovirus. In: Bennett JE, Dolin R, Blaser MJ, Mandell GL, Douglas RG, editors. *Mandell, douglas, and bennett's principles and practice of infectious diseases*. 8th ed. Philadelphia,PA: Elsevier; 2015. p. 1738–53.
 34. Boppana SB, Rivera LB, Fowler KB, et al. Intrauterine transmission of cytomegalovirus to infants of women with preconceptional immunity. *N Engl J Med* 2001;344:1366–71. Available at <https://www.ncbi.nlm.nih.gov/pubmed/11333993>.
 35. Ross SA, Arora N, Novak Z, et al. Cytomegalovirus reinfections in healthy seroimmune women. *J Infect Dis* 2010;201:386–9. Available at <https://www.ncbi.nlm.nih.gov/pubmed/20039807>.
 36. Yamamoto AY, Mussi-Pinhata MM, Boppana SB, et al. Human cytomegalovirus reinfection is associated with intrauterine transmission in a highly cytomegalovirus-immune maternal population. *Am J Obstet Gynecol* 2010;202. 297 e1-8. Available at <https://www.ncbi.nlm.nih.gov/pubmed/20060091>.
 37. Gantt S, Bitnun A, Renaud C, et al. Diagnosis and management of infants with congenital cytomegalovirus infection. *Paediatr Child Health* 2017;22:72–4. Available at <https://www.ncbi.nlm.nih.gov/pubmed/29479184>.
 38. Dworsky M, Yow M, Stagno S, et al. Cytomegalovirus infection of breast milk and transmission in infancy. *Pediatrics* 1983;72:295–9. Available at <https://www.ncbi.nlm.nih.gov/pubmed/6310479>.
 39. Kelly MS, Benjamin DK, Puopolo KM, et al. Postnatal cytomegalovirus infection and the risk for bronchopulmonary dysplasia. *JAMA Pediatr* 2015;169:e153785. Available at <https://www.ncbi.nlm.nih.gov/pubmed/26642118>.
 40. Gunkel J, de Vries LS, Jongmans M, et al. Outcome of preterm infants with postnatal cytomegalovirus infection. *Pediatrics* 2018;141.. Available at <https://www.ncbi.nlm.nih.gov/pubmed/29330315>.
 41. Gonce A, Marcos MA, Borrell A, et al. Maternal igm antibody status in confirmed fetal cytomegalovirus infection detected by sonographic signs. *Prenat Diagn* 2012;32:817–21. Available at <https://www.ncbi.nlm.nih.gov/pubmed/22639067>.
 42. Guerra B, Simonazzi G, Puccetti C, et al. Ultrasound prediction of symptomatic congenital cytomegalovirus infection. *Am J Obstet Gynecol* 2008;198. 380 e1-7. Available at <https://www.ncbi.nlm.nih.gov/pubmed/18191802>.
 43. Rawlinson WD, Boppana SB, Fowler KB, et al. Congenital cytomegalovirus infection in pregnancy and the neonate: Consensus recommendations for prevention, diagnosis, and therapy. *Lancet Infect Dis* 2017;17. e177-e88. Available at <https://www.ncbi.nlm.nih.gov/pubmed/28291720>.
 44. Revello MG, Gerna G. Diagnosis and management of human cytomegalovirus infection in the mother, fetus, and newborn infant. *Clin Microbiol Rev* 2002;15:680–715. Available at <https://www.ncbi.nlm.nih.gov/pubmed/12364375>.
 45. Grazia Revello M, Percivalle E, Zannino M, et al. Development and evaluation of a capture elisa for igm antibody to the human cytomegalovirus major DNA binding protein. *J Virol Methods* 1991;35:315–29.
 46. De Paschale M, Agrappi C, Manco MT, et al. Positive predictive value of anti-hcmv igm as an index of primary infection. *J Virol Methods* 2010;168:121–5. Available at <https://www.ncbi.nlm.nih.gov/pubmed/20470827>.
 47. Prince HE, Lape-Nixon M. Role of cytomegalovirus (cmv) igg avidity testing in diagnosing primary cmv infection during pregnancy. *Clin Vaccine Immunol* 2014;21:1377–84. Available at <https://www.ncbi.nlm.nih.gov/pubmed/25165026>.
 48. Lagrou K, Bodeus M, Van Ranst M, et al. Evaluation of the new architect cytomegalovirus immunoglobulin m (igm), igg, and igg avidity assays. *J Clin Microbiol* 2009;47:1695–9.
 49. Berth M, Grangeot-Keros L, Heskia F, et al. Analytical issues possibly affecting the performance of commercial human cytomegalovirus igg avidity assays. *Eur J Clin Microbiol Infect Dis* 2014;33:1579–84. Available at <https://www.ncbi.nlm.nih.gov/pubmed/24781005>.
 50. Lazzarotto T, Varani S, Guerra B, et al. Prenatal indicators of congenital cytomegalovirus infection. *J Pediatr* 2000;137:90–5. Available at <https://www.ncbi.nlm.nih.gov/pubmed/10891828>.
 51. Lazzarotto T, Spezzacatena P, Pradelli P, et al. Avidity of immunoglobulin g directed against human cytomegalovirus during primary and secondary infections in immunocompetent and immunocompromised subjects. *Clin Diagn Lab Immunol* 1997;4:469–73. Available at <https://www.ncbi.nlm.nih.gov/pubmed/9220166>.
 52. Society for Maternal-Fetal M, Hughes BL, Gyamfi-Bannerman C. Diagnosis and antenatal management of congenital cytomegalovirus infection. *Am J Obstet Gynecol*. 2016;214:B5–B11. Available at <https://www.ncbi.nlm.nih.gov/pubmed/26902990>.
 53. Picone O, Teissier N, Cordier AG, et al. Detailed in utero ultrasound description of 30 cases of congenital cytomegalovirus infection. *Prenat Diagn* 2014;34:518–24. Available at <https://www.ncbi.nlm.nih.gov/pubmed/24532345>.

54. Lazzarotto T, Guerra B, Gabrielli L, et al. Update on the prevention, diagnosis and management of cytomegalovirus infection during pregnancy. *Clin Microbiol Infect* 2011;17:1285–93. Available at <https://www.ncbi.nlm.nih.gov/pubmed/21631642>.
55. Enders G, Bader U, Lindemann L, et al. Prenatal diagnosis of congenital cytomegalovirus infection in 189 pregnancies with known outcome. *Prenat Diagn* 2001;21:362–77. Available at <https://www.ncbi.nlm.nih.gov/pubmed/11360277>.
56. Donner C, Liesnard C, Brancart F, et al. Accuracy of amniotic fluid testing before 21 weeks' gestation in prenatal diagnosis of congenital cytomegalovirus infection. *Prenat Diagn* 1994;14:1055–9. Available at <https://www.ncbi.nlm.nih.gov/pubmed/7877953>.
57. Enders M, Daiminger A, Exler S, et al. Prenatal diagnosis of congenital cytomegalovirus infection in 115 cases: A 5 years' single center experience. *Prenat Diagn* 2017;37:389–98. Available at <https://www.ncbi.nlm.nih.gov/pubmed/28207161>.
58. Leyder M, Vorselemans A, Done E, et al. Primary maternal cytomegalovirus infections: Accuracy of fetal ultrasound for predicting sequelae in offspring. *Am J Obstet Gynecol* 2016;215. 638 e1–e8 Available at <https://www.ncbi.nlm.nih.gov/pubmed/27287685>.
59. Farkas N, Hoffmann C, Ben-Sira L, et al. Does normal fetal brain ultrasound predict normal neurodevelopmental outcome in congenital cytomegalovirus infection? *Prenat Diagn* 2011;31:360–6. Available at <https://www.ncbi.nlm.nih.gov/pubmed/21413035>.
60. Lipitz S, Hoffmann C, Feldman B, et al. Value of prenatal ultrasound and magnetic resonance imaging in assessment of congenital primary cytomegalovirus infection. *Ultrasound Obstet Gynecol* 2010;36:709–717. Available at <https://www.ncbi.nlm.nih.gov/pubmed/20503234>.
61. Lipitz S, Yinon Y, Malinger G, et al. Risk of cytomegalovirus-associated sequelae in relation to time of infection and findings on prenatal imaging. *Ultrasound Obstet Gynecol* 2013;41:508–14. Available at <https://www.ncbi.nlm.nih.gov/pubmed/23288698>.
62. Cannie MM, Devlieger R, Leyder M, et al. Congenital cytomegalovirus infection: Contribution and best timing of prenatal mr imaging. *Eur Radiol* 2016;26:3760–9. Available at <https://www.ncbi.nlm.nih.gov/pubmed/26984434>.
63. Chierighin A, Pavia C, Gabrielli L, et al. Clinical evaluation of the new roche platform of serological and molecular cytomegalovirus-specific assays in the diagnosis and prognosis of congenital cytomegalovirus infection. *J Virol Methods* 2017;248:250–4. Available at <https://www.ncbi.nlm.nih.gov/pubmed/28801056>.
64. Goegebuer T, Van Meensel B, Beuselinck K, et al. Clinical predictive value of real-time per quantification of human cytomegalovirus DNA in amniotic fluid samples. *J Clin Microbiol* 2009;47:660–5. Available at <https://www.ncbi.nlm.nih.gov/pubmed/19109474>.
65. Fabbri E, Revello MG, Furione M, et al. Prognostic markers of symptomatic congenital human cytomegalovirus infection in fetal blood. *BJOG* 2011;118:448–56. Available at <https://www.ncbi.nlm.nih.gov/pubmed/21199291>.
66. Bilavsky E, Shahar-Nissan K, Pardo J, et al. Hearing outcome of infants with congenital cytomegalovirus and hearing impairment. *Arch Dis Child* 2016;101:433–8. Available at <https://www.ncbi.nlm.nih.gov/pubmed/26826174>.
67. Plotkin SA, Boppana SB. Vaccination against the human cytomegalovirus. *Vaccine* 2018. Available at <https://www.ncbi.nlm.nih.gov/pubmed/29622379/>.
68. Pass RF, Zhang C, Evans A, et al. Vaccine prevention of maternal cytomegalovirus infection. *N Engl J Med* 2009;360:1191–9.
69. Pereboom MT, Mannien J, Spelten ER, et al. Observational study to assess pregnant women's knowledge and behaviour to prevent toxoplasmosis, listeriosis and cytomegalovirus. *BMC Pregnancy Childbirth* 2013;13:98.. Available at <https://www.ncbi.nlm.nih.gov/pubmed/23627427>.
70. Willame A, Blanchard-Rohner G, Combescure C, et al. Awareness of cytomegalovirus infection among pregnant women in geneva, switzerland: A cross-sectional study. *Int J Environ Res Public Health* 2015;12:15285–97. Available at <https://www.ncbi.nlm.nih.gov/pubmed/26633451>.
71. Beaudoin ML, Renaud C, Boucher M, et al. Perspectives of women on screening and prevention of cmv in pregnancy. *Eur J Obstet Gynecol Reprod Biol* 2021;258:409–13.
72. Pereboom MT, Mannien J, Spelten ER, et al. Maternal cytomegalovirus infection prevention: The role of dutch primary care midwives. *Midwifery* 2014;30:1196–201. Available at <https://www.ncbi.nlm.nih.gov/pubmed/24832932>.
73. Pereboom MT, Mannien J, van Almkerk KD, et al. What information do dutch midwives give clients about toxoplasmosis, listeriosis and cytomegalovirus prevention? An exploratory study of videotaped consultations. *Patient Educ Couns* 2014;96:29–35. Available at <https://www.ncbi.nlm.nih.gov/pubmed/24820638>.
74. Revello MG, Tibaldi C, Masuelli G, et al. Prevention of primary cytomegalovirus infection in pregnancy. *EBioMedicine* 2015;2:1205–10. Available at <https://www.ncbi.nlm.nih.gov/pubmed/26501119>.
75. Hughes BL, Gans KM, Raker C, et al. A brief prenatal intervention of behavioral change to reduce the risk of maternal cytomegalovirus: A randomized controlled trial. *Obstet Gynecol* 2017;130:726–34. Available at <https://www.ncbi.nlm.nih.gov/pubmed/28885428>.
76. Adler SP, Finney JW, Manganello AM, et al. Prevention of child-to-mother transmission of cytomegalovirus by changing behaviors: A randomized controlled trial. *Pediatr Infect Dis J* 1996;15:240–6. Available at <https://www.ncbi.nlm.nih.gov/pubmed/8852913>.
77. Vauloup-Fellous C, Picone O, Cordier AG, et al. Does hygiene counseling have an impact on the rate of cmv primary infection during pregnancy? Results of a 3-year prospective study in a french hospital. *J Clin Virol* 2009;46(Suppl 4):S49–53. Available at <https://www.ncbi.nlm.nih.gov/pubmed/19811947>.
78. Price SM, Bonilla E, Zador P, et al. Educating women about congenital cytomegalovirus: Assessment of health education materials through a web-based survey. *BMC Womens Health* 2014;14:144.. Available at <https://www.ncbi.nlm.nih.gov/pubmed/25433837>.
79. Thackeray R, Magnusson BM. Women's attitudes toward practicing cytomegalovirus prevention behaviors. *Prev Med Rep* 2016;4:517–24. Available at <https://www.ncbi.nlm.nih.gov/pubmed/27747148>.
80. Thackeray R, Magnusson BM, Christensen EM. Effectiveness of message framing on women's intention to perform cytomegalovirus prevention behaviors: A cross-sectional study. *BMC Womens Health* 2017;17:134.. Available at <https://www.ncbi.nlm.nih.gov/pubmed/29262815>.
81. Balegamire S, McClymont E, Croteau A, et al. Systematic review and meta-analysis of the prevalence, incidence, and risk factors of cytomegalovirus infection in occupationally exposed populations. Under review.
82. Mills JL, Carter TC. Acyclovir exposure and birth defects: An important advance, but more are needed. *JAMA* 2010;304:905–6. <https://doi.org/10.1001/jama.2010.1214>. Available at.
83. Pasternak B, Hviid A. Use of acyclovir, valacyclovir, and famciclovir in the first trimester of pregnancy and the risk of birth defects. *JAMA* 2010;304:859–66. <https://doi.org/10.1001/jama.2010.1206>. Available at.
84. Jacquemard F, Yamamoto M, Costa J-M, et al. Maternal administration of valaciclovir in symptomatic intrauterine cytomegalovirus infection. *BJOG*:

- An International Journal of Obstetrics & Gynaecology 2007;114:1113–21. Available at <https://obgyn.onlinelibrary.wiley.com/doi/abs/10.1111/j.1471-0528.2007.01308.x>.
85. Shahar-Nissan K, Pardo J, Peled O, et al. Valaciclovir to prevent vertical transmission of cytomegalovirus after maternal primary infection during pregnancy: A randomised, double-blind, placebo-controlled trial. *Lancet* 2020;396:779–85.
 86. Jacquemard F, Yamamoto M, Costa JM, et al. Maternal administration of valaciclovir in symptomatic intrauterine cytomegalovirus infection. *BJOG* 2007;114:1113–21. Available at <https://www.ncbi.nlm.nih.gov/pubmed/17617198>.
 87. Leruez-Ville M, Ghout I, Bussieres L, et al. In utero treatment of congenital cytomegalovirus infection with valacyclovir in a multicenter, open-label, phase ii study. *Am J Obstet Gynecol*. 2016;215. 462 e1-e10. Available at <https://www.ncbi.nlm.nih.gov/pubmed/27083761>.
 88. Nigro G, Adler SP, La Torre R, et al. Passive immunization during pregnancy for congenital cytomegalovirus infection. *N Engl J Med* 2005;353:1350–62. Available at <https://www.ncbi.nlm.nih.gov/pubmed/16192480>.
 89. Buxmann H, Stackelberg OM, Schlosser RL, et al. Use of cytomegalovirus hyperimmunoglobulin for prevention of congenital cytomegalovirus disease: A retrospective analysis. *J Perinat Med* 2012;40:439–46. Available at <https://www.ncbi.nlm.nih.gov/pubmed/22752777>.
 90. Revello MG, Lazzarotto T, Guerra B, et al. A randomized trial of hyperimmune globulin to prevent congenital cytomegalovirus. *N Engl J Med* 2014;370:1316–26. Available at <https://www.ncbi.nlm.nih.gov/pubmed/24693891>.
 91. Minsart AF, Smiljkovic M, Renaud C, et al. Use of cytomegalovirus-specific hyperimmunoglobulins in pregnancy: A retrospective cohort. *J Obstet Gynaecol Can* 2018;40:1409–16. Available at <https://www.ncbi.nlm.nih.gov/pubmed/29937136>.
 92. Blazquez-Gamero D, Galindo Izquierdo A, Del Rosal T, et al. Prevention and treatment of fetal cytomegalovirus infection with cytomegalovirus hyperimmune globulin: A multicenter study in madrid. *J Matern Fetal Neonatal Med* 2019;32:617–25. Available at <https://www.ncbi.nlm.nih.gov/pubmed/28978246>.
 93. Kagan KO, Enders M, Schampera MS, et al. Prevention of maternal-fetal transmission of cytomegalovirus after primary maternal infection in the first trimester by biweekly hyperimmunoglobulin administration. *Ultrasound Obstet Gynecol* 2019;53:383–9. Available at <https://www.ncbi.nlm.nih.gov/pubmed/29947159>.
 94. Hughes B. Lb17. Randomized trial to prevent congenital cytomegalovirus (cmv). *Open Forum Infectious Diseases* 2019;6:S1000–S1. <https://doi.org/10.1093/ofid/ofz415.2500>. Available at.
 95. Nigro G, La Torre R, Pentimalli H, et al. Regression of fetal cerebral abnormalities by primary cytomegalovirus infection following hyperimmunoglobulin therapy. *Prenat Diagn* 2008;28:512–7. Available at <https://www.ncbi.nlm.nih.gov/pubmed/18509871>.
 96. Nigro G, Adler SP, Gatta E, et al. Fetal hyperechogenic bowel may indicate congenital cytomegalovirus disease responsive to immunoglobulin therapy. *J Matern Fetal Neonatal Med* 2012;25:2202–5. Available at <https://www.ncbi.nlm.nih.gov/pubmed/22506668>.
 97. Visentin S, Manara R, Milanese L, et al. Early primary cytomegalovirus infection in pregnancy: Maternal hyperimmunoglobulin therapy improves outcomes among infants at 1 year of age. *Clin Infect Dis* 2012;55:497–503. Available at <https://www.ncbi.nlm.nih.gov/pubmed/22539662>.
 98. Nigro G, Adler SP, Parruti G, et al. Immunoglobulin therapy of fetal cytomegalovirus infection occurring in the first half of pregnancy—a case-control study of the outcome in children. *J Infect Dis* 2012;205:215–27. Available at <https://www.ncbi.nlm.nih.gov/pubmed/22140265>.
 99. Japanese Congenital Cytomegalovirus Infection Immunoglobulin Fetal Therapy Study G. A trial of immunoglobulin fetal therapy for symptomatic congenital cytomegalovirus infection. *J Reprod Immunol* 2012;95:73–9. Available at <https://www.ncbi.nlm.nih.gov/pubmed/22884280>.
 100. Kimberlin DW, Jester PM, Sanchez PJ, et al. Valganciclovir for symptomatic congenital cytomegalovirus disease. *N Engl J Med* 2015;372:933–43. Available at <https://www.ncbi.nlm.nih.gov/pubmed/25738669>.
 101. Kimberlin DW, Lin CY, Sanchez PJ, et al. Effect of ganciclovir therapy on hearing in symptomatic congenital cytomegalovirus disease involving the central nervous system: A randomized, controlled trial. *J Pediatr* 2003;143:16–25. Available at <https://www.ncbi.nlm.nih.gov/pubmed/12915819>.
 102. Cannon MJ, Griffiths PD, Aston V, et al. Universal newborn screening for congenital cmv infection: What is the evidence of potential benefit? *Rev Med Virol* 2014;24:291–307. Available at <https://www.ncbi.nlm.nih.gov/pubmed/24760655>.
 103. Gantt S, Dionne F, Kozak FK, et al. Cost-effectiveness of universal and targeted newborn screening for congenital cytomegalovirus infection. *JAMA Pediatr* 2016;170:1173–80. Available at <https://www.ncbi.nlm.nih.gov/pubmed/27723885>.
 104. Diener ML, Zick CD, McVicar SB, et al. Outcomes from a hearing-targeted cytomegalovirus screening program. *Pediatrics* 2017:139.
 105. Gantt S, Brophy J, Dunn J, et al. Ammi canada: Response to faqs about the management of children with congenital cytomegalovirus infection in canada. *Official Journal of the Association of Medical Microbiology and Infectious Disease Canada* 2019;4:208–14. Available at <https://jammi.utpjournals.press/doi/abs/10.3138/jammi.2019-08-21>.
 106. Fowler KB, McCollister FP, Sabo DL, et al. A targeted approach for congenital cytomegalovirus screening within newborn hearing screening. *Pediatrics* 2017:139.